Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about INCY, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Ruxolitinib FDA approved Nov 2011 · Jakafi |
Graft-versus-host Disease (GVHD) | Phase 3 · NCT06615050 | Recruiting |
| Axatilimab (INCA034176) FDA approved Aug 2024 · Niktimvo |
Chronic Graft-versus-host-disease | Phase 3 · NCT06585774 | Recruiting |
| Pemigatinib FDA approved Apr 2020 · Pemazyre |
Bladder Cancer | Phase 2 · NCT03914794 | Active not recruiting |
| Retifanlimab FDA approved Mar 2023 · Zynyz |
Neurofibromatosis Type 2 | Phase 2 · NCT04374305 | Recruiting |
| Investigator's choice of chemotherapy | Solid Tumors | Phase 3 · NCT07522073 | Recruiting |
| KRAS G12D Inhibitor INCB161734 | Solid Tumors | Phase 3 · NCT07522073 | Recruiting |
| CDK2 Inhibitor INCB123667 | Ovarian Cancer | Phase 3 · NCT07214779 | Active not recruiting |
| Povorcitinib | Hidradenitis Suppurativa (HS) | Phase 3 · NCT06855498 | Recruiting |
| Anti-PD-1/Anti-TGFbRII Bispecific Antibody… | CRC (Colorectal Cancer) | Phase 3 · NCT07284849 | Recruiting |
| Anti-mutant Calreticulin Monoclonal Antibody… | Essential Thrombocythemia | Phase 3 · NCT07623200 | Recruiting |
| FOLFOX | CRC (Colorectal Cancer) | Phase 3 · NCT07284849 | Recruiting |
| Ruxolitinib Phosphate Cream | NonSegmental Vitiligo | Phase 3 · NCT06804811 | Recruiting |
| Therapeutic Corticosteroid | Chronic Graft-versus-host-disease | Phase 3 · NCT06585774 | Recruiting |
| Parsaclisib | Non Hodgkins Lymphoma | Phase 1/2 · NCT04661007 | Active not recruiting |
| Ponatinib | Acute Myeloid Leukemia | Phase 1/2 · NCT03934372 | Recruiting |
| JAK Inhibitor | Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 · NCT07228624 | Recruiting |
Also used in these trials (approved or third-party drugs, not INCY's own candidates): Lenalidomide, Cyclophosphamide, Tacrolimus Extended-Release, Tafasitamab, Bevacizumab, Methotrexate, Mycophenolate Mofetil, Nivolumab, Pembrolizumab, Rituximab, Tazemetostat, Azacitidine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
INCY holds $3.9B in cash and short-term investments (as of Sep 30, 2026) and burns about $83.8M/quarter from operations, an estimated runway of 137.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when INCY files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Felix J. Baker | Institution (13G, 5%+) | 31,225,572 | 15.32% | 2026-05-07 |
| Vanguard Capital Management | Institution (13G, 5%+) | 12,591,630 | 6.18% | 2026-03-31 |
| BAKER BROS. ADVISORS LP Director, 10% owner · +6,111 options |
Insider | 314,600 | 0.15% | 2026-09-30 |
| Pablo J Cagnoni President, Global Head of R&D · +136,325 options |
Insider | 183,200 | 0.09% | 2026-10-15 |
| William Meury Chief Executive Officer, Director · +157,569 options |
Insider | 183,129 | 0.09% | 2026-07-16 |
| Mohamed Khairie Issa EVP, Head of U.S. Commercial · +53,561 options |
Insider | 71,797 | 0.04% | 2026-07-16 |
| Patrick A Mayes EVP & Chief Scientific Officer · +48,885 options |
Insider | 61,441 | 0.03% | 2026-08-05 |
| Lee Heeson EVP, Head of Incyte Intl · +28,921 options |
Insider | 37,578 | 0.02% | 2026-10-01 |
| Steven H Stein CMO & Head of Late-Stage Dev. · +131,582 options |
Insider | 30,916 | 0.02% | 2026-11-06 |
| Paul J Clancy Director · +6,111 options |
Insider | 25,838 | 0.01% | 2026-09-30 |
| Edmund Harrigan Director · +6,111 options |
Insider | 23,225 | 0.01% | 2026-09-30 |
| Thomas Tray Principal Accounting Officer · +4,079 options |
Insider | 21,126 | 0.01% | 2026-11-03 |
Share count 203,832,492 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INCY and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →